http://newhope360.com/supply-news-amp-analysis/interhealths-optiberry-shown-inhibit-angiogenesis
Telah menunjukkan OptiBerry yang ketara menghalang angiogenesis kedua-dua in vitro dan in vivo, dengan itu menawarkan potensi manfaat dalam rawatan gangguan yang berkaitan seperti kanser dan radang. Kajian telah diterbitkan dalam Penyelidikan Radikal Bebas dan Persekutuan Biokimia Pertubuhan Eropah (FEBS)
Keselamatan dan keberkesanan Optiberry terbukti menerusi kajian klinikal dari universiti-universiti terkemuka dunia ini :
- Ohio State University Medical Center
- University of Nebraska Medical Center
- Creighton University Medical Center
- Harvard Medical School
- Georgetown University Medical Center
- Universities of California (Berkeley and Davis)
- University of Texas, Department of Health Education
- University of Houston, College of Pharmacy
- University of Connecticut Medical Center
- Long Island University, School of Pharmacy
- Auburn University, Human Performance Laboratory
- Murray State University, Veterinary Center
- Scranton University, Department of Chemistry
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
InterHealth's OptiBerry Shown to Inhibit Angiogenesis
BENICIA, Calif. - June 16, 2003 - Recent studies published in peer-reviewed journals have shown that OptiBerry(TM), a standardized multiple berry extract developed by InterHealth Nutraceuticals (patent-pending), possesses potent anti-angiogenic properties which inhibit the growth of unwanted blood vessels involved in the formation of tumors and varicose veins.
Angiogenesis has become a recent priority in tumor research. CNN reported recently that "Cancer needs a growing network of blood vessels to survive. Shutting down this process, called angiogenesis, should arrest tumors and even obliterate them." Recent clinical trials of an experimental drug, conducted at Duke University, confirmed that cutting off a tumor's blood supply could improve cancer survival.
Researchers at Ohio State University Medical Center (Columbus, Ohio), University of Kuopio (Kuopio, Finland), and Creighton University Medical Center (Omaha, Neb.) have shown that OptiBerry(TM) significantly inhibits angiogenesis both in vitro and in vivo, thus offering potential benefit in the treatment of related disorders such as cancer and inflammation. The studies were published in Free Radical Research and the Federation of European Biochemical Societies (FEBS) Letters.
"The results of this study on OptiBerry(TM), combined with the growing body of research that points to anti-angiogenesis as a potentially powerful weapon in the war against cancer, is truly exciting," stated InterHealth Nutraceuticals President and CEO William Seroy. "The anti-angiogenic benefits of OptiBerry, coupled with its potent antioxidant properties, make it an important natural supplement for today's health-conscious consumers."
OptiBerry was developed by InterHealth after evaluating key functional parameters of numerous berry extracts, including wild blueberry, bilberry, cranberry, elderberry, raspberry and strawberry, and exploring more than 20 extract combinations. OptiBerry was found to be the most potent combination of all berry extract blends tested. In addition to its anti-angiogenic benefits, OptiBerry's antioxidant properties promote brain function and mental clarity, healthy vision, cardiovascular health, and healthy skin. It also helps prevent the effects of premature aging and promotes urinary tract health, while providing blood sugar support.
InterHealth researches and develops specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. In addition to OptiBerry(TM), InterHealth is the maker of Super CitriMax(R), ChromeMate(R), UC-II(TM), Protykin(R), L-OptiZinc(R) and Aller-7(TM). For more information about the company and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit its website at www.InterHealthUSA.com.
Angiogenesis has become a recent priority in tumor research. CNN reported recently that "Cancer needs a growing network of blood vessels to survive. Shutting down this process, called angiogenesis, should arrest tumors and even obliterate them." Recent clinical trials of an experimental drug, conducted at Duke University, confirmed that cutting off a tumor's blood supply could improve cancer survival.
Researchers at Ohio State University Medical Center (Columbus, Ohio), University of Kuopio (Kuopio, Finland), and Creighton University Medical Center (Omaha, Neb.) have shown that OptiBerry(TM) significantly inhibits angiogenesis both in vitro and in vivo, thus offering potential benefit in the treatment of related disorders such as cancer and inflammation. The studies were published in Free Radical Research and the Federation of European Biochemical Societies (FEBS) Letters.
"The results of this study on OptiBerry(TM), combined with the growing body of research that points to anti-angiogenesis as a potentially powerful weapon in the war against cancer, is truly exciting," stated InterHealth Nutraceuticals President and CEO William Seroy. "The anti-angiogenic benefits of OptiBerry, coupled with its potent antioxidant properties, make it an important natural supplement for today's health-conscious consumers."
OptiBerry was developed by InterHealth after evaluating key functional parameters of numerous berry extracts, including wild blueberry, bilberry, cranberry, elderberry, raspberry and strawberry, and exploring more than 20 extract combinations. OptiBerry was found to be the most potent combination of all berry extract blends tested. In addition to its anti-angiogenic benefits, OptiBerry's antioxidant properties promote brain function and mental clarity, healthy vision, cardiovascular health, and healthy skin. It also helps prevent the effects of premature aging and promotes urinary tract health, while providing blood sugar support.
InterHealth researches and develops specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. In addition to OptiBerry(TM), InterHealth is the maker of Super CitriMax(R), ChromeMate(R), UC-II(TM), Protykin(R), L-OptiZinc(R) and Aller-7(TM). For more information about the company and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit its website at www.InterHealthUSA.com.
0 comments:
Post a Comment